

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (PREVIOUSLY PRESENTED) A method for treating a patient having a condition affecting at least one layer of skin comprising administering in situ a physiologically acceptable formulation consisting essentially of at least one hydrolase selective for a layer of skin affected by said condition in an amount and for a duration effective to remove said layer and treat said condition.
2. (ORIGINAL) The method of claim 1 wherein said layer of skin is selected from the group consisting of an epidermal layer, a dermal layer, a subcutaneous layer, and combinations thereof.
3. (CANCELED)
4. (PREVIOUSLY PRESENTED) The method of claim 1 wherein said hydrolase is selected from the group consisting of esterases, glycosidases, proteases, phosphatases, thiolases, phospholipases, amidases, ceramidases, lipases, deaminases, nucleases and combinations thereof.
5. (PREVIOUSLY PRESENTED) The method of claim 1 wherein said hydrolase is selected from the group consisting of trypsin, chymotrypsin, papain, bromelain, dispase,

thermolysin, ceramidase, lipase, glycosidase, deoxyribonuclease, ribonuclease and combinations thereof to treat an epidermal layer.

6. (WITHDRAWN) The method of claim 1 wherein said hydrolase is selected from the group consisting of collagenase, elastase, and combinations thereof to treat a dermal layer.

7. (WITHDRAWN) The method of claim 1 wherein said hydrolase is a lipase to treat a subcutaneous layer.

8. (ORIGINAL) The method of claim 1 where the condition is selected from the group consisting of neoplasms, pigmentary disorders, infectious disorders, follicular disorders, hyperkeratotic disorders, inflammatory disorders, vascular disorders, photo-aging disorders, deposition disorders, connective tissue disorders, and cutaneous cystic disorders.

9. (PREVIOUSLY PRESENTED) The method of claim 1 wherein the hydrolase is selected from the group consisting of trypsin, chymotrypsin, papain, collagenase, pepsin A, elastase, exopeptidases, aminopeptidases, endopeptidases, bromelain, chymotrypsin C, metridin, trypsin, thrombin, plasmin, enteropeptidase, alpha-lytic endopeptidase, prolyl oligopeptidase, bradykinin, plasma kallikrein, tissue kallikrein, pancreatic elastase, leukocyte elastase, chymase, cerevisin, hypodermin C,

endopeptidase La, alpha-renin, leucyl endopeptidase, tryptase, kexin, subtilisin, oryzin, endopeptidase K, thermomycolin, thermitase, endopeptidase So, tissue plasminogen activator, pancreatic endopeptidase E, pancreatic elastase II, urine plasminogen activator, cathepsin B, facain, chymopapain, asclepain, clostripain, streptopain, actinidain, cathepsin L, cathepsin H, calpain, cathepsin T, glycyl endopeptidase, cathepsin S, caricain, ananain, stem bromelain, fruit bromelain, legumain, histolysain, pepsin B, gastricsin, chymosin, cathepsin D, retropepsin, aspergillopepsin I, aspergillopepsin II, penicillopepsin, rhizopuspepsin, endothiapepsin, mucorpepsin, candidapepsin, saccharopepsin, rhodotorulapepsin, physaropepsin, acrocylindropepsin, polyporopepsin, pycnoporopepsin, scytalidopepsin A, scytalidopepsin B, xanthomonoapepsin, pseudomonapepsin, cathepsin E, atrolysin, microbial collagenase, leucolysin, interstitial collagenase, neprilysin, matrix metalloproteinases dispase, thermolysin, V8 protease, ribonuclease, deoxyribonuclease and combinations thereof.

10. (ORIGINAL) The method of claim 1 wherein said administering is selected from the group consisting of topical application, injection, and combinations thereof.

11. (WITHDRAWN) A composition comprising at least one protease selected from the group consisting of trypsin, chymotrypsin, papain, bromelain, dispase, thermolysin, V8 protease, and combinations thereof at a concentration in the range of about $1 \times 10^{-5}\%$ w/v to about 10% w/v in a pharmaceutically acceptable formulation to selectively effect an epidermal layer of skin.

12. (WITHDRAWN) The composition of claim 11 wherein said protease is selected from the group consisting of naturally occurring proteases, synthetic proteases, and combinations thereof.
13. (WITHDRAWN) The composition of claim 11 wherein the concentration of protease is in the range of about $1 \times 10^{-4}\%$ w/v to about 10% w/v.
14. (WITHDRAWN) The composition of claim 11 wherein the concentration of protease is in the range of about 0.1% w/v to about 3.0% w/v.
15. (WITHDRAWN) The composition of claim 11 wherein the formulation is selected from the group consisting of creams, ointments, lotions, liniments, gels, solutions, suspensions, pastes, sticks, sprays, beads, spheres, microbeads, microspheres, liposomes, and combinations thereof.
16. (WITHDRAWN) The composition of claim 11 further containing a co-additive selected from the group consisting of exfoliants, immunomodulating drugs, cytotoxic drugs and combinations thereof.
17. (WITHDRAWN) The composition of claim 16 wherein said exfoliant is selected from the group consisting of ethylenediaminetetracetic acid (EDTA), ethylene

glycol-bis (β -aminoethyl ether)-N,N,N',N'-tetra acetic acid (EGTA), salicylic acid, lactic acid, alpha-hydroxy acids, beta-hydroxy acids, urea and combinations thereof.

18. (WITHDRAWN) The composition of claim 16 wherein said immunomodulating drug is selected from the group consisting of glucocorticoids, tacrolimus, cyclosporin, interferon, ascomycin (SDZ ASM 981), imiquimod, or any of their respective derivatives and their combinations thereof.

19. (WITHDRAWN) The composition of claim 16 wherein said cytotoxic agent is selected from the group consisting of podophyllin, podophylox, cantharadin, and combinations thereof.

20. (WITHDRAWN) A topically applied composition for treating a patient having a skin condition affecting at least one epidermal, and/or dermal layer, and/or subcutaneous layer comprising a hydrolase in a pharmaceutically acceptable formulation, said hydrolase in an amount in the range of about $1 \times 10^{-5}\%$ by weight to about 10% by weight of said formulation.

21. (WITHDRAWN) The composition of claim 20 wherein said hydrolase is selected from the group consisting of esterases, glycosidases, proteases, phosphatases, thiolases, phospholipases, amidases, ceramidases, lipases, deaminases, nucleases and combinations thereof.

22. (WITHDRAWN) The composition of claim 21 wherein said hydrolase is selected from the group consisting of naturally occurring hydrolases, synthetic hydrolases, and combinations thereof.

23. (WITHDRAWN) The composition of claim 21 wherein said protease is selected from the group consisting of collagenases, trypsin, papain, bromelain, streptokinase, chymotrypsin, chymotrypsin C, elastases, exopeptidases, endopeptidases, metridin, thrombin, plasmin, enteropeptidase, alpha-lytic endopeptidase, prolyl oligopeptidase, bradykinin, plasma kallikrein, tissue kallikrein, pancreatic elastase, leukocyte elastase, chymase, cerevisin, hypodermin C, endopeptidase La, alpha-renin, leucyl endopeptidase, tryptase, kexin, subtilisin, oryzin, endopeptidase K, thermomycin, thermolysin, endopeptidase So, tissue plasminogen activator, pancreatic endopeptidase E, pancreatic elastase II, urine plasminogen activator, cathepsin B, papain, ficain, chymopapain, asclepain, clostripain, streptopain, actinidain, cathepsin L, cathepsin H, calpain, cathepsin T, glycyl endopeptidase, cathepsin S, caricain, ananain, stem bromelain, fruit bromelain, legumain, histolysin, pepsin A, pepsin B, gastricsin, chymosin, cathepsin D, retropepsin, aspergillopepsin I, aspergillopepsin II, penicillopepsin, rhizopuspepsin, endothiapepsin, mucorpepsin, candidapepsin, saccharopepsin, rhodotorulapepsin, physaropepsin, acrocylindropepsin, polyporopepsin, pycnoporopepsin, scytalidopepsin A, scytalidopepsin B, xanthomonapepsin, pseudomonapepsin, cathepsin E, atrolisin, microbial collagenase, leucolysin, interstitial collagenase, neprilysin, matrix metalloproteinases, dispase,

thermolysin, V8 protease and combinations thereof.

24. (PREVIOUSLY PRESENTED) A method to treat skin comprising topically applying to an outermost layer of skin a composition consisting essentially of a protease in a biologically acceptable formulation in an amount to selectively remove at least one epidermal layer containing a skin condition to thereby treat said skin.

25. (ORIGINAL) The method of claim 24 wherein said protease is selected from the group consisting of trypsin, papain, bromelain, dispase, thermolysin, and combinations thereof.

26. (WITHDRAWN) A method to treat skin comprising providing a composition consisting essentially of ~~[[containing]]~~ a protease in a biologically acceptable formulation in an amount ~~and formulation~~ to selectively remove at least one dermal layer containing a skin condition to thereby treat said skin.

27. (WITHDRAWN) The method of claim 26 wherein said composition is provided by an administration method selected from the group consisting of topical, injection, and combinations thereof.

28. (WITHDRAWN) The method of claim 26 wherein said protease is selected from the group consisting of collagenases, elastases, and combinations thereof.

29. (WITHDRAWN) A method to treat skin comprising providing a composition containing a lipid hydrolyzing enzyme in a biologically acceptable formulation in an amount and formulation to selectively remove at least one subcutaneous layer containing a skin condition to thereby treat said skin.

30. (CURRENTLY AMENDED) A method to target skin treatment of an affected area comprising providing to said affected area a composition consisting essentially of ~~[[containing]]~~ at least one hydrolase in an amount and formulation effective to selectively target skin removal in said affected area.

31. (ORIGINAL) The method of claim 30 wherein said affected area is selected from the group consisting of epidermis, dermis, subcutaneous layer, and combinations thereof.

32. (WITHDRAWN) A method of treating aging in at least one layer of skin comprising providing a ~~protease-containing~~ biologically acceptable composition consisting essentially of a protease to an outermost layer of affected skin in an amount and formulation to selectively target said affected skin layer.

33. (WITHDRAWN) The method of claim 32 wherein said signs are selected from the group consisting of xerosis, rhytids, loss of skin tone, acitinic damage, fine lines, dyspigmentation, and combinations thereof.

34. (PREVIOUSLY PRESENTED) A method for treating a condition affecting skin comprising applying a composition to the affected skin, the composition containing at least one hydrolase at a concentration selective for regulating depth of skin treatment and applied to an area selective for regulating a radial surface of skin treatment.

35. (PREVIOUSLY PRESENTED) The method of claim 34 wherein the hydrolase is a protease.

36. (ORIGINAL) The method of claim 34 wherein the composition is topically applied.

37. (ORIGINAL) The method of claim 34 wherein the composition comprises a protease and is topically applied.

38. (ORIGINAL) The method of claim 34 wherein the composition is applied one time.

39. (PREVIOUSLY PRESENTED) The method of claim 34 wherein the hydrolase is a protease to treat an epidermal layer.

40. (PREVIOUSLY PRESENTED) The method of claim 34 wherein a relatively short duration of exposure and a relatively low hydrolase concentration is used to treat a condition affecting an epidermal layer.

41. (WITHDRAWN) The method of claim 34 wherein a relatively long duration of exposure and a relatively high hydrolase concentration is used to treat a condition affecting a dermal layer.

42. (WITHDRAWN) The method of claim 8 where the condition is actinic keratosis.

43. (PREVIOUSLY PRESENTED) The method of claim 8 where the condition is seborrheic keratosis.

44. (WITHDRAWN) The method of claim 8 where the condition is condyloma accuminatum (genital wart).

45. (WITHDRAWN) The method of claim 8 where the condition is verruca.

46. (WITHDRAWN) The method of claim 8 where the condition is molluscum contagiosum.

47. (WITHDRAWN) The method of claim 8 where the condition is basal cell carcinoma.

48. (WITHDRAWN) The method of claim 8 where the condition is squamous cell carcinoma.

49. (WITHDRAWN) The method of claim 8 where the condition is squamous cell carcinoma *in situ*.

50. (WITHDRAWN) The method of claim 8 where the condition is hyperpigmentation.

51. (WITHDRAWN) The method of claim 8 where the condition is callus.

52. (WITHDRAWN) The method of claim 8 where the condition is corn.

53. (WITHDRAWN) The method of claim 8 where the condition is fibroepithelial polyp (skin tag).

54. (WITHDRAWN) The method of claim 8 where the condition is melasma.

55. (WITHDRAWN) The method of claim 8 where the condition is scar (cicatrix).

56. (WITHDRAWN) The method of claim 8 where the condition is rhytid (wrinkle).

57. (WITHDRAWN) The method of claim 8 where the condition is acne.
58. (WITHDRAWN) The method of claim 8 where the condition is comedone.
59. (WITHDRAWN) The method of claim 8 where the condition is psoriasis.
60. (WITHDRAWN) The method of claim 8 where the condition is atopic dermatitis.
61. (WITHDRAWN) The method of claim 8 where the condition is xerosis.
62. (WITHDRAWN) The method of claim 8 where the condition is rosacea.
63. (WITHDRAWN) The method of claim 8 where the condition is ichthyosis.


CONCLUSION

Applicant respectfully requests that the Amendment filed on August 27, 2004 along with this corrected listing of claims be considered and that all rejections and objections be withdrawn. Further, applicant believes all claims are in condition for allowance and respectfully request that a Notice of Allowance be granted.

Applicant does not believe there is any fee due with this submission. However, if any fees are necessary, the Commissioner may consider this to be a request for such and charge any necessary fees to Deposit Account 23-3000.

The Examiner is invited to contact applicants' undersigned representative with any issues or questions.

Respectfully submitted,
WOOD, HERRON & EVANS. L.L.P.


Beverly A. Lymah, Ph.D.
Reg. No. 41,961

2700 Carew Tower
441 Vine Street
Cincinnati, OH 45202
(513) 241-2324
(513) 421-7269 facsimile

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.